** U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO, NVO.N down 3.8% at $63.37 premarket
** NVO says Lars Fruergaard Jørgensen is stepping down as CEO, but will stay on for a while to ensure a smooth transition
** Co is looking for a new CEO to replace him, and an announcement will be made soon
** Co says the change in leadership is due to "recent market challenges" and share price decline since mid-2024
** Jørgensen has been with Novo since 1991 and became CEO in 2017
** As of last close, NVO down 23% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))